RET and familial pancreatic carcinoma: While RET alterations are rare in pancreatic cancers, exemplified by report of the first RET fusion-positive pancreatic cancer patient in 2021 (75), patients with aberrant RET pathway activity may benefit from RET-targeted therapies.